SEC Form 3 · accession 0001140361-15-017472
CYTRX CORP · CYTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Jay Selter
Director
Period of report
Apr 30, 2015
Accepted (ET)
May 4, 2015 · 6:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000799698
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| CytRx Common Stock | holding | — | — | — | 27,144 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $4.39 | holding | — | — | — | Apr 30, 2015 | Apr 29, 2025 | CytRx common stock | 180,000 | — | D |
| Stock option (right to buy)F2 | $5.88 | holding | — | — | — | Jul 18, 2005 | Jul 17, 2015 | CytRx Common Stock | 1,071 | — | D |
| Stock option (right to buy) | $7.77 | holding | — | — | — | Jul 18, 2006 | Jul 17, 2016 | CytRx Common Stock | 1,786 | — | D |
| Stock option (right to buy) | $23.31 | holding | — | — | — | Jul 10, 2007 | Jul 9, 2017 | CytRx Common Stock | 1,786 | — | D |
| Stock option (right to buy) | $3.99 | holding | — | — | — | Jul 1, 2008 | Jun 30, 2018 | CytRx Common Stock | 1,786 | — | D |
| Stock option (right to buy) | $8.05 | holding | — | — | — | Jul 1, 2009 | Jun 30, 2019 | CytRx Common Stock | 3,571 | — | D |
| Stock option (right to buy) | $5.46 | holding | — | — | — | Jun 29, 2010 | Jun 28, 2020 | CytRx Common Stock | 3,571 | — | D |
| Stock option (right to buy) | $5.04 | holding | — | — | — | Jun 30, 2011 | Jun 29, 2021 | CytRx Common Stock | 3,571 | — | D |
| Stock option (right to buy) | $2.80 | holding | — | — | — | May 14, 2012 | May 13, 2022 | CytRx Common Stock | 3,571 | — | D |
| Stock option (right to buy) | $1.83 | holding | — | — | — | Dec 10, 2012 | Dec 9, 2022 | CytRx Common Stock | 50,000 | — | D |
| Stock option (right to buy) | $2.39 | holding | — | — | — | Dec 10, 2013 | Dec 9, 2023 | CytRx Common Stock | 90,000 | — | D |
Explanation of responses
- F1This option is Mr. Selter's equity compensation upon becoming a director on CytRx's Board of Directors. The exercise price equals the closing price of CytRx common stock on April 30, 2015, the date Mr. Selter was appointed to the Board.
- F2Prior to joining the CytRx Board of Directors, Eric Selter was given as a gift by his father, Marvin Selter, who was at the time a director on the Board, options totalling 160,713 shares, which equals half of the amount of options granted to Marvin Selter as his equity compensation for service as a director. The option grants are listed individually by year granted.